Using autologous blood transfusion with stem cells to protect bone marrow in cervical cancer patients
Official title: Stored Hematopoietic Stem Cell-containing Autologous Blood Transfusion Therapy for Bone Marrow Protection in Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy
Run by Chongqing University Cancer Hospital · NCT05401175 · Data updated 2026-11-12
This study is testing if giving cervical cancer patients their own blood with stem cells after treatment can help them recover their blood cell production faster and better than standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | Women only |
| Enrollment | 40 (estimated) |
| Sponsor | Chongqing University Cancer Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Status | Recruiting |
| Started | April 13, 2022 |
| Main results expected | April 2027 |
| Study ends | April 2029 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT05401175 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pre-menopausal women aged 18-60 with a confirmed diagnosis of cervical cancer who are eligible for concurrent chemoradiotherapy.
✕Probably not a fit
Patients with existing bone marrow diseases or those with metastases to the central nervous system or bone marrow are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to enhance the recovery of hematopoietic function following chemoradiotherapy in cervical cancer patients through the innovative use of autologous blood transfusions containing hematopoietic stem cells. In a prospective, single-center, non-randomized controlled design, patients will be divided into two groups: one receiving the stem cell transfusion after treatment and the other receiving standard care. The study will monitor the incidence and duration of severe neutropenia and the time taken for hematopoietic recovery, alongside evaluating safety and other secondary endpoints related to treatment delays and adverse events.
Why it matters
Potential benefit: If successful, this approach could significantly improve bone marrow recovery and overall treatment outcomes for cervical cancer patients undergoing chemoradiotherapy.
How similar studies have gone: While the use of stem cell support in cancer treatment is established, the specific application of autologous blood transfusion for bone marrow protection in cervical cancer is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1)18-60 years old; 2)there are radiotherapy and chemotherapy indicators for cervical cancer;3)pathological diagnosis of squamous, adenocarcinoma or adenosquamous carcinoma;4)the Eastern Cooperative Oncology Group (ECOG) performance status score≤1; 5)the expected survival time was more than 3 months; 6)pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;7)all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;8)the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations. Exclusion Criteria: 1\) clinical diagnosis of bone marrow disease;2) imaging or pathological diagnosis of central nervous system or soft meningeal or bone or bone marrow metastases;3)patient has severe cardiac insufficiency;4)previous history of allogeneic stem cell transplantation or organ transplantation;5)patients with active bleeding and autoimmune thrombocytopenic purpura;6)patients with radiochemotherapy contraindications;7)positive for human immunodeficiency virus (HIV);8)acute or chronic active hepatitis B or hepatitis C infection;9)History of gastrointestinal perforation and/or fistula, clinical signs or symptoms of intestinal obstruction and/or gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection complicated by chronic diarrhoea), Crohn's disease, ulcerative colitis or chronic diarrhoea within the previous 6 months;10)evidence of an intra-abdominal pneumoperitoneum that cannot be explained by puncture or recent surgical intervention.
Where it's running
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China Recruiting
Study contacts
- Principal investigator: Dongling Zou, M.D. — Chongqing University Cancer Hospital
- Study coordinator: Dongling Zou, M.D.
- Email: cqzl_zdl@163.com
- Phone: 13657690699
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.